JC
PVLA

JBF Capital’s Palvella Therapeutics PVLA Stock Holding History

JBF Capital’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,250
Closed -$335K – 84
2019
Q1 		$335K Hold
1,250
– – 0.06% 49
2018
Q4 		$266K Buy
+1,250
New +$388K 0.05% 45

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

JBF Capital's PVLA Position: Q2 2019 in Review

JBF Capital sold out of Palvella Therapeutics (PVLA) in Q2 2019, closing a stake of 1,250 shares — an estimated $335K sold.

JBF Capital first reported a position in PVLA in Q4 2018 and held it in 2 quarters. The position peaked at $335K in Q1 2019. 93 funds tracked by Wall St. Rank hold PVLA as of Q2 2019.

  • JBF Capital reported no remaining Palvella Therapeutics position as of Q2 2019 after selling out during the quarter.
  • JBF Capital sold 1,250 Palvella Therapeutics shares in Q2 2019, an estimated $335K.
  • JBF Capital first reported a position in Palvella Therapeutics in Q4 2018 and held it in 2 quarters.
  • JBF Capital's Palvella Therapeutics position peaked at $335K in Q1 2019.
  • 93 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2019.

Based on JBF Capital's 13F filing for Q2 2019, filed 9 Aug 2019.